ArticleAmerican journal of translational research2022
YY1 as a promoter regulating the circ_0001946/miR-671-5p/EGFR axis to promote chemotherapy resistance in breast cancer cells.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Clinical Significance of Nuclear Yin-Yang Overexpression Evaluated by Immunohistochemistry in Tissue Microarrays and Digital Pathology Analysis: A Useful Prognostic Tool for Breast Cancer.International journal of molecular sciences · 2025Article
- YY1 mediated DCUN1D5 transcriptional activation promotes triple-negative breast cancer progression by targeting FN1/PI3K/AKT pathway.Biology direct · 2024Article
- The circRNA-0001361/miR-491/FGFR4 axis is associated with axillary response evaluated by ultrasound following NAC in subjects with breast cancer.Biochemistry and biophysics reports · 2023Article
- YY1 transcription factor induces proliferation and aerobic glycolysis of neuroblastoma cells via LDHA regulation.Experimental and therapeutic medicine · 2023Article
- A review on the role of miR-671 in human disorders.Frontiers in molecular biosciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the mechanism of circ_0001946 activated by transcription factor Yin Yang 1 (YY1), targeting miR-671-5p to regulate epidermal growth factor receptor (EGFR) and thereby participating in the chemotherapy resistance of breast cancer (BC) cells.
methodsCirc_0001946, which is differentially expressed in BC, was screened using gene expression omnibus. Dual luciferase assay and RNA immunoprecipitation were conducted to verify the relationship among circ_0001946/miR-671-5p/EGFR. A ChIP test confirmed that YY1 can be used as a transcription factor of circ_0001946 to specifically bind to its promoter. The expression of circ_0001946/miR-671-5p/EGFR regulatory axis in BC tissues and cell lines were evaluated using qRT-PCR. As for
resultsCirc_0001946 showed an abnormally high expression in BC tissues and tamoxifen resistant cells and was up-regulated in an IC
conclusionCirc_0001946 absorbs miR-671-5p to target EGFR to promote the growth and malignant invasion of drug-resistant BC cells, thereby increasing the resistance to tamoxifen. This effect of circ_0001946 may be achieved by transcriptional activation of YY1.
Indexed as
Identifiers
35559420PMC9091114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.